Please call to speak with our registered nurse.
for more information.
By Denise Mann
TUESDAY, Jan. 24 (HealthDay News) -- New research suggests that Avodart, a drug used to treat an enlarged prostate gland, may help slow the progression of early stage prostate cancer, reducing the need for aggressive treatment in some men.
Prostate cancer can grow and spread slowly, which is why some men are urged to engage in so-called watchful waiting when the cancer is first diagnosed. Avodart (dutasteride) may help such men feel comfortable with surveillance as opposed to radical treatment, the researchers noted.
"The concept of active surveillance is gaining traction in most parts of the world," said study author Dr. Neil E. Fleshner, head of the division of urology at the Princess Margaret Hospital in Toronto. Still, some men are uncomfortable with doing nothing in the face of a cancer diagnosis, he said. "By using this drug, we can improve the proportion of men who remain committed to the surveillance."
The findings are published online Jan. 25 in The Lancet.
According to the U.S. National Cancer Institute, one out of every six men in the United States will develop prostate cancer in his lifetime. But because many of those cancers are low-grade, most will die of something else.
Avodart belongs to a class of drugs called 5-alpha reductase inhibitors. These drugs work by interfering with the effects of certain male hormones on the prostate. In the three-year study, prostate cancer progressed in 38 percent of 144 men with early prostate cancer who were treated with Avodart and 48 percent of the 145 men who received a placebo.
Men seem less anxious about the cancer diagnosis when they are doing something more proactive, Fleshner said. "The drug augments active surveillance and avoids most of the side effects associated with surgery and radiation," he said. Prostate removal surgery and/or radiation can lead to impotence and incontinence, he said.
The medication does have side effects, however, including reversible breast enlargement and tenderness and some sexual dysfunction.
"We know that we are over-treating prostate cancer," said Dr. Louis Potters, chairman of radiation medicine at North Shore University Hospital and Long Island Jewish Medical Center in Manhasset, N.Y.
"In the U.S., patients have a tendency to hear the word 'cancer,' and want to treat it right away," he said. "In these men with early prostate cancer, we can now say, 'Let's put you on this medication, and see what happens over the next couple of months.'"
However, some experts have concerns about 5-alpha reductase inhibitors. The U.S. Food and Drug Administration recently issued a warning that men who take these drugs to treat enlarged prostate glands may be at increased risk for high-grade prostate cancer.
Dr. Ryan Terlecki, an assistant professor of urology at Wake Forest Baptist Medical Center in Winston-Salem, N.C., said this may dampen enthusiasm for use of the drug to treat cancer.
"The overall role that these medications will play for urologists will decrease," Terlecki said. Doctors will likely begin looking toward noninvasive and/or non-medical treatments such as the use of thermal heat to cope with some of the symptoms of prostate conditions, he added.
Learn more about prostate cancer at the American Cancer Society.
SOURCES: Neil E. Fleshner, M.D., head, division of urology, Princess Margaret Hospital, Toronto; Louis Potters, M.D., chairman, radiation medicine, North Shore University Hospital and LIJ Medical Center, Manhasset, N.Y.; Ryan Terlecki, M.D., assistant professor, urology, Wake Forest University, Winston-Salem, N.C.; Jan. 25, 2012, The Lancet, online
Copyright © 2012 HealthDay. All rights reserved.
BLADDERVOID BRINGS IMMEDIATE RELIEF TO MEN WITH ENLARGED PROSTATES
PHILADELPHIA (Oct. 2, 2012) – In a world filled with pricey, high-tech innovations, a new low-tech medical device is catching the attention of urologists nationwide as a way to improve the lives of men battling the discomforts that come with enlarged prostates or BPH (benign prostatic hyperplasia).
BladderVoid is a patented medical device created by healthcare professionals that provides a deep, soothing and long-lasting heat to the bladder muscle enabling men to urinate and empty the bladder completely. The device also works with initiating the double voiding technique recommended by the Mayo Clinic.
BladderVoid is shaped like a miniature neck and shoulder heat wrap, but anatomically designed to fit the male groin region. After heating the BladderVoid gel pack in the microwave for approximately one minute, men can wrap it around the genital area while urinating to relax the bladder muscle. After about 30 seconds, the bladder muscle relaxes and the urge to urinate is stimulated allowing a man to empty his bladder completely.
The BladderVoid device was invented by Mark Brown who originated the idea after witnessing his father’s struggles at a hospital to get urine samples after a stroke.
"BladderVoid is really helpful for patients who want to avoid the expense and dependency of medications designed to increase the flow of urination," says Dr. Peter Sinaiko, an urologist based near Philadelphia.
"There are a lot of side effects that come with drugs and much discomfort with catheters; it’s refreshing to recommend something to patients that is easy to use and not so invasive."
According to the American Urological Association, half of all men have BPH by age 60. The majority of men report only mild BPH symptoms, which according to Dr. Sinaiko, can often be treated through lifestyle changes and home remedies such as BladderVoid.
BladderVoid can be purchased online at: www.bladdervoid.com or in select Walgreens drug stores ($29.95 SRP). The device is reusable and comes with a washable, terrycloth sleeve. To learn more about BladderVoid, visit: www.bladdervoid.com.